Premium
Enhancement of permeability in endothelial cells for the development of an antithrombogenic bioartificial hemofilter
Author(s) -
Vu Duc M.,
Yokoyama Tun A.,
Sawada Kaichiro,
Inagaki Miho,
Kanai Genta,
Lu Jianxin,
Kakuta Takatoshi,
Adler Stephen,
Nangaku Masaomi,
Saito Akira
Publication year - 2008
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.21918
Subject(s) - cytochalasin d , umbilical vein , chemistry , endothelial stem cell , permeability (electromagnetism) , endothelium , biophysics , microfilament , cell , biology , medicine , biochemistry , membrane , in vitro , cytoskeleton
For the development of an antithrombogenic bioartificial hemofilter, in which the inner surface of hollow fibers is lined by endothelial cells, it is essential to increase the permeability of the cells in order to achieve a sufficient ultrafiltrate. We tried to increase it by using an actin microfilament polymerization inhibitor, cytochalasin B (CyB). Fifty µg/mL CyB was added for 2 h to the culture medium of confluent rat glomerular endothelial cells (RGEC) and human umbilical vein endothelial cells (HUVEC). Under the 130 mmHg hydrostatic pressure, the CyB‐treated group produced significantly more ultrafiltration than the non‐treated control group and this increase was maintained for at least 7 days. Horseradish peroxidase (HRP) permeability acutely and reversibly increased in the CyB‐treated group compared with the non‐treated control group. Scanning electron microscopy revealed a larger average diameter and increased number of fenestrae on the CyB‐treated endothelial cells, compared with the non‐treated cells. This phenomenon also lasted for at least 7 days. The platelet adherence test showed that CyB did not deteriorate the antithrombogenic property of endothelial cells. These results indicate that CyB is potentially applicable for the enhancement of endothelial cell permeability in an antithrombogenic bioartificial hemofilter. Biotechnol. Bioeng. 2008;101: 634–641. © 2008 Wiley Periodicals, Inc.